JMS-17-2 hydrochloride Biochemical | JMS-17-2 biochemical

JMS-17-2 hydrochloride

CATALOG #
AAA228331

PRODUCT SYNONYMS

JMS-17-2 hydrochloride; JMS-17-2 biochemical

PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2341841-07-2
Targets&IC50	CX3CR1:0.32 nM (IC50)
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	JMS-17-2 (10 mg/kg; aministered i.p.; twice a day for three weeks) causes a dramatic reduction of tumors in both skeleton and visceral organs in SCID mice[1]. Animal Model: SCID mice (~25g) with MDA-231 xenograft[1]. Dosage: 10 mg/kg. Administration: Aministered i.p.; twice a day for three weeks. Result: Caused a dramatic reduction of tumors in both skeleton and visceral organs.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES

Structure
AV-153, CAS 27296-05-5

Structure
AV-153, CAS 27296-05-5

ADDITIONAL INFORMATION

Related Product Information for JMS-17-2 biochemical	JMS-17-2 hydrochloride is a potent and selective CX3CR1 antagonist with an IC 50 of 0.32 nM. JMS-17-2 hydrochloride impairs metastatic seeding and colonization of breast cancer cells.
References	1. Nadezhda I Ryabokon, et al. A 1,4-dihydropyridine Derivative Reduces DNA Damage and Stimulates DNA Repair in Human Cells in Vitro. Mutat Res. 2005 Nov 10;587(1-2):52-8. 2. E Buraka, et al. DNA-binding Studies of AV-153, an Antimutagenic and DNA Repair-Stimulating Derivative of 1,4-dihydropiridine. Chem Biol Interact. 2014 Sep 5;220:200-7.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: https://stage.aaabiotech.com/biochemical/jms-17-2-hydrochloride/228331